NCT07098364
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +20 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Clinical trial condition
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Explore clinical trials studying Recurrent Primary Mediastinal Large B-Cell Lymphoma. Study availability and eligibility vary by location and protocol.
8 public trials
5 recruiting studies
Recurrent Primary Mediastinal Large B-Cell Lymphoma trial results
NCT06536049
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +22 more
- Locations
-
- University of Minnesota/Masonic Cancer Center Minneapolis, Minnesota, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
NCT06784726
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +20 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
NCT07365306
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +16 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
- City of Hope Atlanta Cancer Center Newnan, Georgia, United States
- City of Hope at Chicago Zion, Illinois, United States
NCT06834373
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +39 more
- Locations
-
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Florida Jacksonville, Florida, United States
- Mayo Clinic Health System in Albert Lea Albert Lea, Minnesota, United States
- Mayo Clinic Health Systems-Mankato Mankato, Minnesota, United States
NCT03484819
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +12 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
- HaysMed Hays, Kansas, United States
- University of Kansas Cancer Center Kansas City, Kansas, United States
Active, Not Recruiting
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
NCT03038672
- Conditions
- ALK-Positive Large B-Cell Lymphoma, Burkitt Lymphoma, DNA Virus Infections, +53 more
- Locations
-
- Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Florida Jacksonville, Florida, United States
- Moffitt Cancer Center-International Plaza Tampa, Florida, United States
Active, Not Recruiting
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
NCT05359211
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +17 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States